Mastocytosis
For patient information, click here
Mastocytosis | |
Skin: Cutaneous Mastocytosis; childhood form (A), there is a tumoral dermal infiltrate devoid of epidermotropism and composed of bland cells with conspicuous cell boundaries and uniform, round, centrally located nuclei (B). Confirmatory cytoplasmic granules are only apparent with metachromatic stains, such as this Giemsa stain (C), or by upon ultrastructural examination (D). C, X1000. D, X65,000. Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology | |
ICD-10 | Q82.2, C96.2 |
ICD-9 | 757.33, 202.6 |
ICD-O: | 9741/3 |
OMIM | 154800 |
DiseasesDB | 7864 |
MeSH | D008415 |
Mastocytosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Mastocytosis On the Web |
American Roentgen Ray Society Images of Mastocytosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Classification
Historical Perspective
Pathophysiology
Epidemiology & Demographics
Risk Factors
Screening
Causes
Differentiating Mastocytosis from other Diseases
Natural History, Complications & Prognosis
Diagnosis
History & Symptoms | Physical Examination | Staging | Lab Tests | Electrocardiogram | Chest X Ray | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention
Additional Resources
- Based on an informative page by the National Institute of Allergy and Infectious Diseases (NIAID).
- Shah NP, Lee FJ, Luo R, Jiang Y, Donker M, Akin C. Dasatinib (BMS-354825) inhibits KIT(D816V), an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006; 108(1):286-291. PMID 16434489.
- Pardanani A, Teffer A. Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature. Current Opinion in Hematology. 2010; 17(2): 125-132. PMID 20075725.